606 related articles for article (PubMed ID: 31705130)
1. From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer.
Nevala-Plagemann C; Hidalgo M; Garrido-Laguna I
Nat Rev Clin Oncol; 2020 Feb; 17(2):108-123. PubMed ID: 31705130
[TBL] [Abstract][Full Text] [Related]
2. New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma.
Singh RR; O'Reilly EM
Drugs; 2020 May; 80(7):647-669. PubMed ID: 32306207
[TBL] [Abstract][Full Text] [Related]
3. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
[TBL] [Abstract][Full Text] [Related]
4. Clinical Trials of Systemic Chemotherapy for Resectable Pancreatic Cancer: A Review.
Mavros MN; Moris D; Karanicolas PJ; Katz MHG; O'Reilly EM; Pawlik TM
JAMA Surg; 2021 Jul; 156(7):663-672. PubMed ID: 33787841
[TBL] [Abstract][Full Text] [Related]
5. Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy.
Farren MR; Sayegh L; Ware MB; Chen HR; Gong J; Liang Y; Krasinskas A; Maithel SK; Zaidi M; Sarmiento JM; Kooby D; Patel P; El-Rayes B; Shaib W; Lesinski GB
JCI Insight; 2020 Jan; 5(1):. PubMed ID: 31830001
[TBL] [Abstract][Full Text] [Related]
6. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
7. Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges.
Diab M; Azmi A; Mohammad R; Philip PA
Expert Opin Pharmacother; 2019 Apr; 20(5):535-546. PubMed ID: 30592647
[TBL] [Abstract][Full Text] [Related]
8. Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future.
Pokorny AMJ; Chin VT; Nagrial AM; Yip D; Chantrill LA
Intern Med J; 2018 Jun; 48(6):637-644. PubMed ID: 29898269
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis.
Choi JG; Nipp RD; Tramontano A; Ali A; Zhan T; Pandharipande P; Dowling EC; Ferrone CR; Hong TS; Schrag D; Fernandez-Del Castillo C; Ryan DP; Kong CY; Hur C
Oncologist; 2019 Jul; 24(7):945-954. PubMed ID: 30559125
[TBL] [Abstract][Full Text] [Related]
10. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
11. Next-generation therapies for pancreatic cancer.
Buckley CW; O'Reilly EM
Expert Rev Gastroenterol Hepatol; 2024; 18(1-3):55-72. PubMed ID: 38415709
[TBL] [Abstract][Full Text] [Related]
12. Targeting DNA damage repair pathways in pancreas cancer.
Crowley F; Park W; O'Reilly EM
Cancer Metastasis Rev; 2021 Sep; 40(3):891-908. PubMed ID: 34403012
[TBL] [Abstract][Full Text] [Related]
13. Pancreas cancer: Therapeutic trials in metastatic disease.
Smithy JW; O'Reilly EM
J Surg Oncol; 2021 May; 123(6):1475-1488. PubMed ID: 33831245
[TBL] [Abstract][Full Text] [Related]
14. Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal.
Mundry CS; Eberle KC; Singh PK; Hollingsworth MA; Mehla K
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188387. PubMed ID: 32579889
[TBL] [Abstract][Full Text] [Related]
15. Novel Therapeutics for Pancreatic Adenocarcinoma.
Lowery MA; O'Reilly EM
Hematol Oncol Clin North Am; 2015 Aug; 29(4):777-87. PubMed ID: 26226910
[TBL] [Abstract][Full Text] [Related]
16. Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma.
Capello M; Lee M; Wang H; Babel I; Katz MH; Fleming JB; Maitra A; Wang H; Tian W; Taguchi A; Hanash SM
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26025324
[TBL] [Abstract][Full Text] [Related]
17. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study.
Wainberg ZA; Bekaii-Saab T; Boland PM; Dayyani F; Macarulla T; Mody K; Belanger B; Maxwell F; Moore Y; Thiagalingam A; Wang T; Zhang B; Dean A
Eur J Cancer; 2021 Jul; 151():14-24. PubMed ID: 33957442
[TBL] [Abstract][Full Text] [Related]
18. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic ductal adenocarcinoma: time for a neoadjuvant revolution?
Salvia R; Malleo G; Maggino L; Milella M; Bassi C
Updates Surg; 2020 Jun; 72(2):321-324. PubMed ID: 32445032
[No Abstract] [Full Text] [Related]
20. Molecular targets for diagnostic and intraoperative imaging of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX treatment.
Vuijk FA; de Muynck LDAN; Franken LC; Busch OR; Wilmink JW; Besselink MG; Bonsing BA; Bhairosingh SS; Kuppen PJK; Mieog JSD; Sier CFM; Vahrmeijer AL; Verheij J; Fariňa-Sarasqueta A; Swijnenburg RJ
Sci Rep; 2020 Oct; 10(1):16211. PubMed ID: 33004930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
